5d8j - Revision history

OCA at 10:25, 21 June 2023

OCA — Wed, 21 Jun 2023 10:25:44 GMT

←Older revision		Revision as of 10:25, 21 June 2023
Line 1:		Line 1:

	==Development of a therapeutic monoclonal antibody targeting secreted aP2 to treat type 2 diabetes.==		==Development of a therapeutic monoclonal antibody targeting secreted aP2 to treat type 2 diabetes.==
-	<StructureSection load='5d8j' size='340' side='right' caption='[[5d8j]], [[Resolution\|resolution]] 3.00Å' scene=''>	+	<StructureSection load='5d8j' size='340' side='right'caption='[[5d8j]], [[Resolution\|resolution]] 3.00Å' scene=''>
	== Structural highlights ==		== Structural highlights ==
-	<table><tr><td colspan='2'>[[5d8j]] is a 3 chain structure with sequence from [~~http~~://en.wikipedia.org/wiki/~~Lk3_transgenic_mice Lk3 transgenic mice~~]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=5D8J OCA]. For a <b>guided tour on the structure components</b> use [~~http~~://~~oca~~.~~weizmann.ac.il/oca-docs~~/fgij/fg.htm?mol=5D8J FirstGlance]. <br>	+	<table><tr><td colspan='2'>[[5d8j]] is a 3 chain structure with sequence from [https://en.wikipedia.org/wiki/Mus_musculus Mus musculus]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=5D8J OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=5D8J FirstGlance]. <br>
-	</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=SO4:SULFATE+ION'>SO4</scene>~~</td></tr>~~	+	</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=SO4:SULFATE+ION'>SO4</scene></td></tr>
-	~~<tr id='related'><td class="sblockLbl"><b>[[Related_structure\|Related:]]</b></td><td class="sblockDat">[[5c0n\|5c0n]]</td></tr>~~	+	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=5d8j FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=5d8j OCA], [https://pdbe.org/5d8j PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=5d8j RCSB], [https://www.ebi.ac.uk/pdbsum/5d8j PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=5d8j ProSAT]</span></td></tr>
-	<tr id='gene'><td class="sblockLbl"><b>[[Gene\|Gene:]]</b></td><td class="sblockDat">Fabp4, Ap2 ([http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&srchmode=5&id=10090 LK3 transgenic mice])</td></tr>	+
-	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[~~http~~://~~oca~~.~~weizmann.ac.il/oca-docs~~/fgij/fg.htm?mol=5d8j FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=5d8j OCA], [~~http~~://pdbe.org/5d8j PDBe], [~~http~~://www.rcsb.org/pdb/explore.do?structureId=5d8j RCSB], [~~http~~://www.ebi.ac.uk/pdbsum/5d8j PDBsum], [~~http~~://prosat.h-its.org/prosat/prosatexe?pdbcode=5d8j ProSAT]</span></td></tr>	+
	</table>		</table>
	== Function ==		== Function ==
-	[~~[http~~://www.uniprot.org/uniprot/FABP4_MOUSE FABP4_MOUSE]] Lipid transport protein in adipocytes. Binds both long chain fatty acids and retinoic acid. Delivers long-chain fatty acids and retinoic acid to their cognate receptors in the nucleus.<ref>PMID:12077340</ref> <ref>PMID:16574478</ref> <ref>PMID:17516629</ref>	+	[https://www.uniprot.org/uniprot/FABP4_MOUSE FABP4_MOUSE] Lipid transport protein in adipocytes. Binds both long chain fatty acids and retinoic acid. Delivers long-chain fatty acids and retinoic acid to their cognate receptors in the nucleus.<ref>PMID:12077340</ref> <ref>PMID:16574478</ref> <ref>PMID:17516629</ref>
	<div style="background-color:#fffaf0;">		<div style="background-color:#fffaf0;">
	== Publication Abstract from PubMed ==		== Publication Abstract from PubMed ==
Line 20:		Line 18:
	</div>		</div>
	<div class="pdbe-citations 5d8j" style="background-color:#fffaf0;"></div>		<div class="pdbe-citations 5d8j" style="background-color:#fffaf0;"></div>
		+
		+	==See Also==
		+	*[[Fatty acid-binding protein 3D structures\|Fatty acid-binding protein 3D structures]]
		+	*[[Monoclonal Antibodies 3D structures\|Monoclonal Antibodies 3D structures]]
	== References ==		== References ==
	<references/>		<references/>
	__TOC__		__TOC__
	</StructureSection>		</StructureSection>
-	[[Category: ~~Lk3 transgenic mice~~]]	+	[[Category: Large Structures]]
-	[[Category: ~~Birrane, G~~]]	+	[[Category: Mus musculus]]
-	[[Category: ~~Doyle, C~~]]	+	[[Category: Birrane G]]
-	[[Category: ~~Ap2]]~~	+	[[Category: Doyle C]]
-	~~[[Category: Diabetes]]~~	+
-	~~[[Category: Fabp4]]~~	+
-	~~[[Category: Immune system]]~~	+
-	~~[[Category: Metabolic syndrome~~]]	+

OCA at 03:11, 16 November 2017

OCA — Thu, 16 Nov 2017 03:11:35 GMT

←Older revision		Revision as of 03:11, 16 November 2017
Line 1:		Line 1:
		+
	==Development of a therapeutic monoclonal antibody targeting secreted aP2 to treat type 2 diabetes.==		==Development of a therapeutic monoclonal antibody targeting secreted aP2 to treat type 2 diabetes.==
	<StructureSection load='5d8j' size='340' side='right' caption='[[5d8j]], [[Resolution\|resolution]] 3.00Å' scene=''>		<StructureSection load='5d8j' size='340' side='right' caption='[[5d8j]], [[Resolution\|resolution]] 3.00Å' scene=''>
	== Structural highlights ==		== Structural highlights ==
-	<table><tr><td colspan='2'>[[5d8j]] is a 3 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=5D8J OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=5D8J FirstGlance]. <br>	+	<table><tr><td colspan='2'>[[5d8j]] is a 3 chain structure with sequence from [http://en.wikipedia.org/wiki/Lk3_transgenic_mice Lk3 transgenic mice]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=5D8J OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=5D8J FirstGlance]. <br>
	</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=SO4:SULFATE+ION'>SO4</scene></td></tr>		</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=SO4:SULFATE+ION'>SO4</scene></td></tr>
	<tr id='related'><td class="sblockLbl"><b>[[Related_structure\|Related:]]</b></td><td class="sblockDat">[[5c0n\|5c0n]]</td></tr>		<tr id='related'><td class="sblockLbl"><b>[[Related_structure\|Related:]]</b></td><td class="sblockDat">[[5c0n\|5c0n]]</td></tr>
-	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=5d8j FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=5d8j OCA], [http://pdbe.org/5d8j PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=5d8j RCSB], [http://www.ebi.ac.uk/pdbsum/5d8j PDBsum]</span></td></tr>	+	<tr id='gene'><td class="sblockLbl"><b>[[Gene\|Gene:]]</b></td><td class="sblockDat">Fabp4, Ap2 ([http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&srchmode=5&id=10090 LK3 transgenic mice])</td></tr>
		+	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=5d8j FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=5d8j OCA], [http://pdbe.org/5d8j PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=5d8j RCSB], [http://www.ebi.ac.uk/pdbsum/5d8j PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=5d8j ProSAT]</span></td></tr>
	</table>		</table>
	== Function ==		== Function ==
Line 22:		Line 24:
	__TOC__		__TOC__
	</StructureSection>		</StructureSection>
		+	[[Category: Lk3 transgenic mice]]
	[[Category: Birrane, G]]		[[Category: Birrane, G]]
	[[Category: Doyle, C]]		[[Category: Doyle, C]]

OCA at 20:07, 13 January 2016

OCA — Wed, 13 Jan 2016 20:07:05 GMT

←Older revision		Revision as of 20:07, 13 January 2016
Line 1:		Line 1:
-	'''~~Unreleased~~ structure'''	+	==Development of a therapeutic monoclonal antibody targeting secreted aP2 to treat type 2 diabetes.==
		+	<StructureSection load='5d8j' size='340' side='right' caption='[[5d8j]], [[Resolution\|resolution]] 3.00Å' scene=''>
		+	== Structural highlights ==
		+	<table><tr><td colspan='2'>[[5d8j]] is a 3 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=5D8J OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=5D8J FirstGlance]. <br>
		+	</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=SO4:SULFATE+ION'>SO4</scene></td></tr>
		+	<tr id='related'><td class="sblockLbl"><b>[[Related_structure\|Related:]]</b></td><td class="sblockDat">[[5c0n\|5c0n]]</td></tr>
		+	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=5d8j FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=5d8j OCA], [http://pdbe.org/5d8j PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=5d8j RCSB], [http://www.ebi.ac.uk/pdbsum/5d8j PDBsum]</span></td></tr>
		+	</table>
		+	== Function ==
		+	[[http://www.uniprot.org/uniprot/FABP4_MOUSE FABP4_MOUSE]] Lipid transport protein in adipocytes. Binds both long chain fatty acids and retinoic acid. Delivers long-chain fatty acids and retinoic acid to their cognate receptors in the nucleus.<ref>PMID:12077340</ref> <ref>PMID:16574478</ref> <ref>PMID:17516629</ref>
		+	<div style="background-color:#fffaf0;">
		+	== Publication Abstract from PubMed ==
		+	The lipid chaperone aP2/FABP4 has been implicated in the pathology of many immunometabolic diseases, including diabetes in humans, but aP2 has not yet been targeted for therapeutic applications. aP2 is not only an intracellular protein but also an active adipokine that contributes to hyperglycemia by promoting hepatic gluconeogenesis and interfering with peripheral insulin action. Serum aP2 levels are markedly elevated in mouse and human obesity and strongly correlate with metabolic complications. These observations raise the possibility of a new strategy to treat metabolic disease by targeting serum aP2 with a monoclonal antibody (mAb) to aP2. We evaluated mAbs to aP2 and identified one, CA33, that lowered fasting blood glucose, improved systemic glucose metabolism, increased systemic insulin sensitivity, and reduced fat mass and liver steatosis in obese mouse models. We examined the structure of the aP2-CA33 complex and resolved the target epitope by crystallographic studies in comparison to another mAb that lacked efficacy in vivo. In hyperinsulinemic-euglycemic clamp studies, we found that the antidiabetic effect of CA33 was predominantly linked to the regulation of hepatic glucose output and peripheral glucose utilization. The antibody had no effect in aP2-deficient mice, demonstrating its target specificity. We conclude that an aP2 mAb-mediated therapeutic constitutes a feasible approach for the treatment of diabetes.

-	~~The entry 5d8j is ON HOLD until Paper Publication~~	+	Development of a therapeutic monoclonal antibody that targets secreted fatty acid-binding protein aP2 to treat type 2 diabetes.,Burak MF, Inouye KE, White A, Lee A, Tuncman G, Calay ES, Sekiya M, Tirosh A, Eguchi K, Birrane G, Lightwood D, Howells L, Odede G, Hailu H, West S, Garlish R, Neale H, Doyle C, Moore A, Hotamisligil GS Sci Transl Med. 2015 Dec 23;7(319):319ra205. doi: 10.1126/scitranslmed.aac6336., Epub 2015 Dec 23. PMID:26702093<ref>PMID:26702093</ref>

-	~~Authors: Doyle~~, C.~~, Birrane, G~~.	+	From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br>
-		+	</div>
-	~~Description: Development~~ of ~~a therapeutic monoclonal antibody targeting secreted aP2 to treat type 2 diabetes~~.	+	<div class="pdbe-citations 5d8j" style="background-color:#fffaf0;"></div>
-	~~[[Category~~: ~~Unreleased Structures]]~~	+	== References ==
		+	<references/>
		+	__TOC__
		+	</StructureSection>
	[[Category: Birrane, G]]		[[Category: Birrane, G]]
	[[Category: Doyle, C]]		[[Category: Doyle, C]]
		+	[[Category: Ap2]]
		+	[[Category: Diabetes]]
		+	[[Category: Fabp4]]
		+	[[Category: Immune system]]
		+	[[Category: Metabolic syndrome]]

OCA at 12:46, 30 September 2015

OCA — Wed, 30 Sep 2015 12:46:41 GMT

←Older revision		Revision as of 12:46, 30 September 2015
Line 1:		Line 1:
	'''Unreleased structure'''		'''Unreleased structure'''

-	The entry 5d8j is ON HOLD	+	The entry 5d8j is ON HOLD until Paper Publication

	Authors: Doyle, C., Birrane, G.		Authors: Doyle, C., Birrane, G.

OCA: Protected "5d8j" [edit=sysop:move=sysop]

OCA — Wed, 26 Aug 2015 12:33:34 GMT

Protected "5d8j" [edit=sysop:move=sysop]

←Older revision

Revision as of 12:33, 26 August 2015

OCA: New page: '''Unreleased structure''' The entry 5d8j is ON HOLD Authors: Doyle, C., Birrane, G. Description: Development of a therapeutic monoclonal antibody targeting secreted aP2 to treat type ...

OCA — Wed, 26 Aug 2015 12:33:33 GMT

New page: '''Unreleased structure''' The entry 5d8j is ON HOLD Authors: Doyle, C., Birrane, G. Description: Development of a therapeutic monoclonal antibody targeting secreted aP2 to treat type ...

New page

'''Unreleased structure'''

The entry 5d8j is ON HOLD

Authors: Doyle, C., Birrane, G.

Description: Development of a therapeutic monoclonal antibody targeting secreted aP2 to treat type 2 diabetes.
[[Category: Unreleased Structures]]
[[Category: Birrane, G]]
[[Category: Doyle, C]]